Ten-year experience with primary ocular 'reticulum cell sarcoma' (large cell non-Hodgkin's lymphoma).

Siegel, Marc J.; Dalton, Jack; Friedman, Alan H.; Strauchen, James A.; Watson, Carolyn

doi:10.1136/bjo.73.5.342

Cited by 67 publications

(20 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…6,78 For disease limited to the eye, radiotherapy alone (30 Gy to both eyes 20,79 ) often led to a prolonged disease-free state. 20 Ocular recurrences were common, and most patients developed CNS disease within 14 to 84 months.…”

Section: Historical Overviewmentioning

confidence: 99%

Intraocular Lymphoma: Update on Diagnosis and Management

2004

View full text Add to dashboard Cite

Background: Primary intraocular lymphoma (PIOL) is a subset of primary central nervous system lymphoma (PCNSL) in which lymphoma cells initially invade the retina, vitreous, or optic nerve head From the Laboratory of Immunology at the National Eye Institute, National Institutes of Health, Bethesda, Maryland. Submitted January 20, 2004; accepted April 12, 2004. Address correspondence to Chi-Chao Chan, MD, Laboratory of Immunology, National Eye Institute, National Institutes of Health, 10 Center Drive, Building 10, Room 10N103, Bethesda, MD 20892. E-mail: chanc@nei.nih.gov No significant relationship exists between the authors and the companies/organizations whose products or services may be referenced in this article.Abbreviations used in this paper: CSF = cerebrospinal fluid; IgH = heavy chain immunoglobulin; mbr = major breakpoint region; mcr = minor cluster region; MTX = methotrexate; PCNSL = primary central nervous system lymphoma; PIOL = primary intraocular lymphoma; RPE = retinal pigment epithelium.

show abstract

Section: Historical Overviewmentioning

confidence: 99%

Intraocular Lymphoma: Update on Diagnosis and Management

2004

View full text Add to dashboard Cite

show abstract

“…Few cases were described in B-cell IOL 31,37,39 and T-cell IOL. 3 Severe bilateral CME was present in one of our patients.…”

Section: Discussionmentioning

confidence: 99%

Intraocular T-cell Lymphoma: Clinical Presentation, Diagnosis, Treatment, and Outcome

Chaput

Amer

Baglivo

et al. 2016

Ocular Immunology and Inflammation

View full text Add to dashboard Cite

“…Most groups now advocate combination therapy, employing both EBRT and systemic or intrathecal chemotherapy, primarily methotrexate based, to enhance the response to irradiation [11,48]. With this method the results have been modest, with none of the reviewed literature showing complete response in all treated eyes ( Table 1).…”

Section: Radiation Therapymentioning

confidence: 99%

The evaluation and treatment of primary intraocular lymphoma

Hanson¹,

Alexandru²,

Bota³

2013

J Cancer Ther Res

View full text Add to dashboard Cite

Primary intraocular lymphoma (PIOL) is a relatively rare form of Non-Hodgkin's Lymphoma arising in the lymphoid tissues of the eye. It is highly correlated with primary CNS lymphoma (PCNSL) and it is estimated that up to 80% of patients presenting with PIOL will eventually manifest intracranial malignancy, which is the largest contributor to mortality. Most patients present with nonspecific visual symptoms, including floaters and blurry vision, and are often initially diagnosed with uveitis or retinitis. Definitive diagnosis requires biopsy of malignant tissues with demonstration of malignant lymphoid cells. Optimal therapy is to this point undefined, and the available literature is limited to case reports and retrospective series. Currently employed therapies include the use of localized external beam radiation therapy (EBRT), whole brain radiation therapy (WBRT), systemic chemotherapy, intrathecal chemotherapy, and, most recently, direct intravitreal (IVT) chemotherapy. While radiation therapy and chemotherapy can produce a high response rate, they have not been shown to effectively prevent relapse or the incidence of CNS spread. Methotrexate has been the most popular therapy used for the treatment of intraocular lymphoma. It has been administered systemically, intrathecally or intravitreally. However due to multiple mechanisms of resistance developed by lymphoma cells against methotrexate, this drug has been unable to prevent disease recurrence. The newest, and perhaps most promising, reported therapy includes the use of rituximab anti-CD20 monoclonal antibody either alone or in combination chemotherapy via intrathecal or IVT administration. Most cases in the literature employ combinations of available therapies, and there are no comparative studies of significant power to date. Multicenter collaboration will be required to determine the true relative efficacy and adversity of the therapeutic options available.

show abstract

Ten-year experience with primary ocular 'reticulum cell sarcoma' (large cell non-Hodgkin's lymphoma).

Cited by 67 publications

References 17 publications

Intraocular Lymphoma: Update on Diagnosis and Management

Intraocular Lymphoma: Update on Diagnosis and Management

Intraocular T-cell Lymphoma: Clinical Presentation, Diagnosis, Treatment, and Outcome

The evaluation and treatment of primary intraocular lymphoma

Contact Info

Product

Resources

About